CD8A and neoplasm: Furthermore, hIL7/mIL12-VV generated gp70 tumor antigen-specific (gp70+CD8+) T cells in both injected and distant CT26.WT tumors (Fig. 2; Table 1), reinforcing its systemic antitumor immune effect [30].